Conventional diuretic agents are very effective agents in relieving volume overload and congestive symptoms in chronic heart failure (CHF). However, they are associated with activation of the renin-angiotensin system (RAS) and the sympathetic nervous system and a reduction in glomerular filtration rate, all of which have been associated with adverse outcomes in CHF. Therefore, there is an increasing interest in drugs that target the natriuretic system without neurohormonal activation and deterioration of renal function. In this review, we will discuss the underlying rationale and evidence behind currently pursued strategies that target the natriuretic system. This includes the administration of natriuretic peptides (NPs) and strategies that potentiate the NP system, such as neutral endopeptidase inhibition. We will also highlight some potentially important interactions of these strategies with drugs that target the RAS.
Mann DLMechanisms and models in heart failure: a combinatorial approach. Circulation1999;100:999-1008.
2.
Costello-Boerrighter LC, Boerrigter G., Burnett JC Jr.Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin N Am2003;87:475-91.
3.
Francis GS, Benedict C., Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A sub-study of the studies of Left Ventricular Dysfunction (SOLVD). Circulation1990;82:1724-9.
4.
Dries DL, Exner DV, Domanski MJ, Greenberg B., Stevenson LWThe prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol2000;35:681-9.
5.
Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC, Jr.Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res1988;62:191-5.
6.
Kim JK, Summer SN, Durr J., Schrier RWEnzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. Kidney Int1989;35:799-805.
7.
Mendez RE, Dunn BR,Troy JL, Brenner BMModulation of the natriuretic response to atrial natriuretic peptide by alterations in peritubular Starling forces in the rat. Circ Res1986; 59:605-11.
8.
Abraham WT, Hensen J., Kim JK et al. Atrial natriuretic peptide and urinary cyclic guanosine monophosphate in patients with chronic heart failure. J Am Soc Nephrol1992; 2:1697-703.
9.
Wu CF,* Bishopric NH, Pratt REAtrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes . J Biol Chem1997;272:14860-6.
10.
Cao L., Gardner DGNatriuretic peptides inhibit DNA synthesis in cardiac fibroblasts . Hypertension1995;25:227-34.
11.
Cody RJ,Atlas SA, Laragh JH et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest1986;78:1362-74.
12.
Lang CC, Prasad N., McAlpine HM et al. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. Am Heart J1994;127:1635-6.
13.
Choy AM, Darbar D., Lang CC et al. Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods . Br Heart J1994;72:16-22.
14.
Darbar D., Davidson NC, Gillespie N. et al. Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. Am J Cardiol1996;78:284-7.
15.
Latini R., Masson S., Anand I. et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation2002 ;106:2454-8.
16.
Berger R., Huelsman M., Strecker K. et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation2002 ;105:2392-7.
17.
Abraham WT, Lowes BD, Ferguson DA et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Cardiac Failure1998;4:37-44.
18.
Brunner-La Rocca HP, Kaye DM,Woods RL, Hastings J., Esler MDEffects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol2001;37:1221-7.
19.
Schweitz H. , Vigne P., Moinier D., Frelin C., Lazdunski M.A new member of the natriuretic peptide family is present in the venom of the Green Mamba (Dendroaspis angusticeps). J Biol Chem1992 ;267:13928-32.
20.
Collins E., Bracamonte MP, Burnett JC, Jr., Miller VMMechanism of relaxations to dendroaspis natriuretic peptide in canine coronary arteries. J Cardiovasc Pharmacol2000;35: 614-18.
21.
Lang CC, Motwani JG, Coutie WJ, Struthers ADClearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci1992;82:619-23.
22.
Colucci WS, Elkayam U., Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med2000;343:246-53.
23.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.JAMA2002;287:1531-40.
24.
Burger AJ, Horton DP, LeJemtel T. et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J2002;144:1102-08.
25.
Saito H., OgiharaT,Nakamaru M. et al. Hemodynamic, renal, and hormonal responses to alpha-human atrial natriuretic peptide in patients with congestive heart failure. Clin Pharmacol Ther1987;42:142-7.
26.
Munzel T., Kurz S., Holtz J. et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure . Circulation1992;86:1089-98.
27.
Lisy O., Jougasaki M., Heublein D. et al. Renal actions of synthetic Dendroaspis natriuretic peptide. Kidney Int1999;56:502-08.
28.
Burnett JC Jr.Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens1997;17(suppl 1): S37-S43.
29.
Robl JA, Sun CQ, Stevenson J. et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem1997 ;40:1570-7.
30.
Wegner M., Hirth-Dietrich C., Stasch JPRole of neutral endopeptidase 24.11 in AV fistular rat model of heart failure . Cardiovasc Res1996;31:891-8.
31.
Wilkins MR, Settle SL, Stockmann PT, Needleman P.Maximizing the natriuretic effect of endogenous atriopeptin in a rat model of heart failure. Proc Natl Acad Sci USA1990 ; 87:6465-9.
32.
Maki T., Nasa Y., Yamaguchi F. et al. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res2001;51:608-17.
33.
Kimura M., Umemura K., Ohashi K., Nakashima M.Effect of ecadotril, a neutral endopeptidase inhibitor, on myocardial hypertrophy in the rat aortic insufficiency model. Can J Cardiol1998;14:63-8.
34.
Richards M. , Espiner E., Frampton C. et al. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension1990;16:269-76.
Seymour AA, Fennell SA, Swerdel JNPotentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29,072. Hypertension1989;14:87-97.
37.
Northridge DB, JardineA,Henderson E., Dilly SG, Dargie HJIncreased circulating atrial natriuretic factor concentrations in patients with chronic heart failure after inhibition of neutral endopeptidase: effects on diastolic function. Br Heart J1992; 68:387-91.
38.
Lang CC, Motwani J., Coutie WJ, Struthers ADInfluence of candoxatril on plasma brain natriuretic peptide in heart failure .[erratum appears in Lancet1991 ;338:255.
39.
Good JM, Peters M., Wilkins M., Jackson N., Oakley CM, Cleland JGRenal response to candoxatrilat in patients with heart failure. J Am Coll Cardiol1995;25:1273-81.
40.
Elsner D., Muntze A., Kromer EP, Riegger GAEffectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol1992;70:494-8.
41.
Newby DE, McDonagh T., Currie PF, Northridge DB, Boon NA, Dargie HJCandoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Eur Heart J1998;19:1808-13.
42.
Northridge DB, Currie PF, Newby DE et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail1999;1:67-72.
43.
Margulies KB , Barclay PL, Burnett JC, Jr.The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation1995;91:2036-42.
44.
Kohzuki M., Hodsman GP, Johnston CIAttenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol1989;256:H533-8.
45.
Knecht M., Pagel I., Langenickel T. et al. Increased expression of renal neutral endopeptidase in severe heart failure. Life Sci2002;71:2701-12.
46.
RayaTE,Lee RW,Westhoff T. et al. Captopril restores hemodynamic responsiveness to atrial natriuretic peptides in rats with heart failure. Circulation1989;80:1886-92.
47.
Lee RW, Raya TE, Michael U. et al. Captopril and ANP: changes in renal hemodynamics, glomerularANP receptors and guanylate cyclase activity in rats with heart failure. J Pharmacol Exp Ther1992;260:349.
48.
Campbell DJ , Anastopoulos F., Duncan AM, Jamed GM, Kladis A.,Briscoe TAEffects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther1998 ;287:567-77.
49.
Duncan AM, James GM,Anastasopoulos F., Kladis A., Briscoe TA, Campbell DJInteraction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels. J Pharmacol Exp Ther1999;289:295-303.
50.
Rademaker MT , Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T.Combined neutral endopeptidase and angiotensin converting enzyme inhibition in heart failure: Role of natriuretic peptides and angiotensin II. J Cardiovasc Pharmacol1998;31(1):116-25.
51.
Gros C., Noel N., Souque A. et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA1991;88:4210-14.
52.
Corti R., Burnett JC, Jr., Rouleau JL, Ruschitzka F., Luscher TFVasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?Circulation2001;104:1856-62.
53.
Trippodo NC , Fox M., Monticello TM, Panchal BC, Asaad MMVasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol1999;34:782-90.
54.
Chen HH, Lainchbury JG, Matsuda Y., Harty GJ, Burnett JC, Jr.Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension2001;38:187-91.
55.
Thomas CV, McDaniel GM, Holzgrefe HH et al. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol1998;32:902-12.
56.
Maki T., Nasa Y.,Tanonaka K.,Takahashi M.,Takeo S.Beneficial Effects of Sampatrilat, a Novel Vasopeptidase Inhibitor, on Cardiac Remodeling and Function of Rats with Chronic Heart Failure following Left Coronary Artery Ligation. J Pharmacol Exp Ther2003;305:97-105.
57.
Rouleau JL, Pfeffer MA, Stewart DJ et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.[comment][erratum appears in Lancet2000 Nov 18;356(9243):1774]. Lancet2000;356:615-20.
58.
Eisenstein EL, Nelson CL, Simon TA, SmittenAL,Lapuerta P., Mark DBVasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. Am Heart J2002;143:1112-17.
59.
Sheth T., Parker T., Block A. et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol2002;90:496-500.
60.
Packer M., Califf RM, Konstam MA et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation2002;106:920-6.
61.
Coats AJOmapatrilat-the story of Overture and Octave. Int J Cardiol2002;86:1-4.
62.
Regamey F., Maillard M., Nussberger J., Brunner HR, Burnier M.Renal haemodynamic and natriuretic effects of concomitant angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension2002;40:266-72.
63.
Lainchbury JG, Mark RA, Nicholls MG, Espiner EA, Yandle TGBrain natriuretic peptide and neutral endopeptidase inhibition in left ventricular impairment . J Clin Endocrinol Metab1999;84:723-9.
64.
Richards AM , Crozier IG, Yandle TG, Espiner EA, Ikram H., Nicholls MGBrain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease . Br Heart J1993 ;69:414-17.
65.
Chen HH, Lainchbury JG, Harty GJ, Burnett JC, Jr.Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition . Circulation2002;105:999-1003.
66.
Pitt B., Zannad F., Remme WJ, Cody R., Castaigne A., Perez A., et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. (RALES) Randomized Aldactone Evaluation Study Investigators . N Engl J Med1999;341:709-17.
67.
Weber KTAldosterone in congestive heart failure. N Engl J Med2001;345:1689-97.
68.
Bauersachs J., Fraccarollo D., Ertl G., Gretz N., Wehling M., Christ M.Striking increase of natriuresis by low dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES . Circulation2000;102:2325-8.
69.
Jolobe OMEfficacy of low dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis. J Hepatol1993;19: 321-2.
70.
Nishida N., Ogawa T., Yamauchi T. et al. Treatment of cilazapril, an angiotensin converting enzyme inhibitor, changes the affinity of arginine receptor in the kidney of the spontaneousLy hypertensive rat. Res Commun Chem Pathol1994 ;84:14352.
71.
Farquharson CA, Struthers ADSpironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/ angiotensin II conversion in patients with chronic heart failure. Circulation2000;101:594-7.
72.
Bauersachs J., Heck M., Fraccarollo D. et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction . J Am Coll Cardiol2002;39:351-8.
73.
EPHESUS Investigators.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med2003;348:1309-21.
74.
Krum H., Nolly H.,Workman D. et al.Efficacy of eplerenone added to renin angiotensin blockade in hypertensive patients. Hypertension2000;40:117-23.
75.
Schafer A., Fraccarollo D., Hildemann SK, Tas P., Ertl G., Bauersachs J.Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: Effect on endothelial dysfunction. Cardiovasc Res2003 (in press).
76.
Lonn E., McKelvie R.Drug treatment in heart failure. BMJ2000;320:1188-92.
77.
Gottlieb SS , Skettino SL, Wolff A. et al. Effects of BG 9719 (CVT-124), an A1-adenosine receptor antagonist and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure . J Am Coll Cardiol2000; 35:56-9.
78.
Gottlieb SS , Brater DC, Thomas I. et al. BG 97119 (CVT-124), an A1-adenosine receptor antagonist protects against the decline in renal function observed with diuretic therapy. Circulation2002;105:1348-53.
79.
OhnishiA.,OrituY. ,Okahara R. et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest1993;92:2653-9.
80.
Palm C., Reimann D., Gross P.The role of vasopressin V2-antagonists in hyponatremia. Cardiovasc Res2001;51:403-08.
81.
Udelson JE, Smith WB, Hendrix GH et al. Acute hemodynamic effects of conivapton, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation2001;104:2417-23.
